12.04.2018
Biofrontera AG DE0006046113
DGAP-Adhoc: Biofrontera AG: Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018
DGAP-Ad-hoc: Biofrontera AG / Key word(s): Quarter Results/Development of
Sales
Biofrontera AG: Biofrontera announces preliminary unaudited sales revenues
for the 1st Quarter 2018
12-Apr-2018 / 14:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biofrontera announces preliminary unaudited sales revenues for the 1st
Quarter 2018
Leverkusen, Germany, 12 April 2018 - Biofrontera AG (NASDAQ ticker symbol:
BFRA, ISIN: DE0006046113), the specialist for the treatment of sun-induced
skin cancer, today announced preliminary unaudited revenue for the first
quarter of fiscal year 2018.
The preliminary unaudited revenues of Biofrontera group for the period
January to March 2018 were between 4.6 and 4.7 million euros. This
corresponds to a sales growth of approx. 80% compared to the previous year,
with pure product sales increasing by approximately 107%.
Preliminary unaudited quarterly product sales in the USA are expected to be
approximately EUR 3.4 million, compared to EUR 1.3 million in the same
period in 2017; product sales in Germany and Europe will be approximately
EUR 1.2 million, compared to EUR 0.9 million in Q1 2017.
Overall, sales in the first quarter of 2018 were thus significantly higher
than in the previous year and are further proof of the company's successful
growth strategy.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: [email protected]
---------------------------------------------------------------------------
12-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of Announcement DGAP News Service
---------------------------------------------------------------------------
674013 12-Apr-2018 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biofrontera AG ISIN: DE0006046113 können Sie bei EQS abrufen
Biotechnologie , 604611 , B8F , XETR:B8F